Acadia Pharmaceuticals Files 8-K Report
Ticker: ACAD · Form: 8-K · Filed: 2024-03-11T00:00:00.000Z
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: ACAD
TL;DR
ACAD filed an 8-K, check for updates.
AI Summary
On March 11, 2024, Acadia Pharmaceuticals Inc. filed an 8-K report. The filing primarily serves as a notification of other events, with no specific material events detailed in the provided text. The company is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This 8-K filing indicates Acadia Pharmaceuticals is making a regulatory disclosure. Investors should review the full filing for details on any material events that may impact the company's stock.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high risk.
Key Players & Entities
- ACADIA PHARMACEUTICALS INC (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
- March 11, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Acadia Pharmaceuticals Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' as of March 11, 2024.
When was this 8-K report filed by Acadia Pharmaceuticals Inc.?
This 8-K report was filed on March 11, 2024.
In which state is Acadia Pharmaceuticals Inc. incorporated?
Acadia Pharmaceuticals Inc. is incorporated in Delaware.
What is the principal executive office address for Acadia Pharmaceuticals Inc.?
The principal executive office address is 12830 El Camino Real, Suite 400, San Diego, California, 92130.
Does the provided text detail any specific material events or financial information?
No, the provided text is a standard 8-K header and does not detail specific material events or financial information.
Filing Stats: 417 words · 2 min read · ~1 pages · Grade level 11.9 · Accepted 2024-03-11 16:05:55
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- d786050d8k.htm (8-K) — 22KB
- 0001193125-24-064791.txt ( ) — 140KB
- acad-20240311.xsd (EX-101.SCH) — 3KB
- acad-20240311_lab.xml (EX-101.LAB) — 18KB
- acad-20240311_pre.xml (EX-101.PRE) — 11KB
- d786050d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acadia Pharmaceuticals Inc. Dated: March 11, 2024 By: /s/ Jennifer J. Rhodes Jennifer J. Rhodes Executive Vice President, Chief Legal Officer & Secretary